EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

José Manuel Carrascosa, Vimal H Prajapati, H Chih-Ho Hong iD, Viktoria Eleftheriadou, Athanasios Tsianakas, Alexander A Navarini iD, Ketty Peris iD, Eingun James Song, Raj Chovatiya iD, Sébastien Barbarot iD, Konstantin Popovic, Haq Nawaz und 3 weitere

Journal of the European Academy of Dermatology and Venereology · 20.07.2026

DOI: 10.1111/jdv.70595 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 20.07.2026. Verfasst von José Manuel Carrascosa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitari Germans Trias i Pujol, Universitat Autònoma of Barcelona, IGTP, Badalona, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Incyte Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently control AD signs/symptoms, and escalation to systemic therapy may be required.

Objectives

Report 8‐week results of ruxolitinib cream in TRuE‐AD4 (NCT06238817) in patients with moderate AD who had an inadequate response/intolerance/contraindication to TCS and TCI in the past 12 months (post‐TCS and ‐TCI).

Methods

Patients aged ≥18 years with AD, an Investigator's Global Assessment (IGA) of 3, Eczema Area and Severity Index (EASI) >7, itch numerical rating scale (NRS) ≥4, 10%–20% affected body surface area and Dermatology Life Quality Index score > 10 post‐TCS and ‐TCI were randomized (2:1) to twice‐daily 1.5% ruxolitinib cream or vehicle for 8 weeks. Coprimary endpoints at Week 8 were ≥75% improvement in EASI from baseline (EASI‐75) and IGA score of 0/1 with a ≥ 2‐point improvement from baseline (IGA treatment success [TS]).

Results

Of 241 randomized patients (mean age, 37.0 y; 54.4% female), mean EASI and itch NRS scores were 12.6 and 7.4, respectively, at baseline. At Week 8, significantly more patients who applied 1.5% ruxolitinib cream versus vehicle achieved IGA‐TS (61.3% vs. 13.6%; p < 0.0001) and EASI‐75 (70.0% vs. 18.5%; p < 0.0001). Significantly more patients achieved a ≥ 4‐point improvement in itch NRS (itch NRS4) at Day 2 (29.8% vs. 13.7%; p = 0.0072); improvement in current itch (no recall) was observed in 15 min after the first application. No treatment‐related adverse events were serious, and the most common adverse event occurring with ruxolitinib cream was application site acne (3.8%).

Conclusions

In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream significantly improved clinical signs of AD, rapidly improved itch and was well tolerated. Thus, ruxolitinib cream may represent an effective topical option before escalation to systemic therapy in patients with moderate AD.

Schlagwörter

Stichwörter der Autor:innen

atopic eczemaclinical trialpruritusquality of liferuxolitinib

Autor:innen und Institutionen

  • Hospital Universitari Germans Trias i Pujol, Universitat Autònoma of Barcelona, IGTP, Badalona, Spain.
  • University of Calgary, Calgary, Alberta, Canada.
  • Dermatology Research Institute, Calgary, Alberta, Canada.
  • Skin Health & Wellness Centre, Calgary, Alberta, Canada.
  • Probity Medical Research, Calgary, Alberta, Canada.
  • University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: H Chih-Ho Hong, Alexander A Navarini, Ketty Peris, Raj Chovatiya, Sébastien Barbarot, Andreas Wollenberg

Förderung

  • Incyte Corporation

Zitieren

APA

Carrascosa, J. M., Prajapati, V. H., Hong, H. C., Eleftheriadou, V., Tsianakas, A., Navarini, A. A., Peris, K., Song, E. J., Chovatiya, R., Barbarot, S., Popovic, K., Nawaz, H., Li, Q., Purohit, V., & Wollenberg, A. (2026). Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70595

Vancouver

Carrascosa JM, Prajapati VH, Hong HC, Eleftheriadou V, Tsianakas A, Navarini AA, et al. Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70595

BibTeX
@article{Carrascosa2026,
  author = {Carrascosa, José Manuel and Prajapati, Vimal H and Hong, H Chih-Ho and Eleftheriadou, Viktoria and Tsianakas, Athanasios and Navarini, Alexander A and Peris, Ketty and Song, Eingun James and Chovatiya, Raj and Barbarot, Sébastien and Popovic, Konstantin and Nawaz, Haq and Li, Qian and Purohit, Vivek and Wollenberg, Andreas},
  title = {Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70595}
}
Kostenlos starten →